Vimarsana.com

Latest Breaking News On - News ratings for actinium pharmaceuticals daily - Page 1 : vimarsana.com

Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) Given Consensus Recommendation of "Buy" by Brokerages

Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM – Get Free Report) has been assigned a consensus rating of “Buy” from the six analysts that are covering the company, MarketBeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokers that have issued a report on the stock in […]

Creative-financial-designs-inc
Actinium-pharmaceuticals-trading
Institutional-trading-of-actinium-pharmaceuticals
Sanders-morris-harris
Cantor-fitzgerald
Actinium-pharmaceuticals
Analyst-recommendations-for-actinium-pharmaceuticals
News-ratings-for-actinium-pharmaceuticals-daily
Virtu-financial
Actinium-pharmaceuticals-inc
Maxim-group

Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) Receives $25.60 Consensus Target Price from Analysts

Shares of Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM – Get Free Report) have earned an average rating of “Buy” from the six brokerages that are presently covering the firm, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation. The average 1 year target price among brokers that have covered the stock […]

Cantor-fitzgerald
Creative-financial-designs-inc
Hedge-funds-weigh-in-on-actinium-pharmaceuticals
Analyst-recommendations-for-actinium-pharmaceuticals
Vanguard-group-inc
Actinium-pharmaceuticals
Brandywine-global-investment-management
Actinium-pharmaceuticals-stock-performance
Actinium-pharmaceuticals-company-profile
Virtu-financial
News-ratings-for-actinium-pharmaceuticals-daily

HC Wainwright Reaffirms Buy Rating for Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)

HC Wainwright reiterated their buy rating on shares of Actinium Pharmaceuticals (NYSEAMERICAN:ATNM – Free Report) in a research note issued to investors on Tuesday morning, Benzinga reports. HC Wainwright currently has a $50.00 target price on the biotechnology company’s stock. Several other research analysts also recently commented on ATNM. Cantor Fitzgerald reaffirmed an overweight rating […]

Actinium-pharmaceuticals-company-profile
Sanders-morris-harris
News-ratings-for-actinium-pharmaceuticals-daily
Maxim-group
Cantor-fitzgerald
Actinium-pharmaceuticals-inc
Creative-financial-designs-inc
Actinium-pharmaceuticals
Vanguard-group-inc
Virtu-financial
Actinium-pharmaceuticals-price-performance

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Rating Reiterated by HC Wainwright

HC Wainwright reiterated their buy rating on shares of Actinium Pharmaceuticals (NYSEAMERICAN:ATNM – Free Report) in a report published on Tuesday morning, Benzinga reports. The brokerage currently has a $50.00 target price on the biotechnology company’s stock. Other analysts have also recently issued reports about the stock. Stephens initiated coverage on shares of Actinium Pharmaceuticals […]

Vanguard-group-inc
Sanders-morris-harris
Institutional-investors-weigh-in-on-actinium-pharmaceuticals
Actinium-pharmaceuticals-company-profile
News-ratings-for-actinium-pharmaceuticals-daily
Cantor-fitzgerald
Actinium-pharmaceuticals
Creative-financial-designs-inc
Virtu-financial
Analyst-recommendations-for-actinium-pharmaceuticals
Actinium-pharmaceuticals-price-performance

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Upgraded to Hold by StockNews.com

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Upgraded to Hold by StockNews.com
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Sanders-morris-harris
Actinium-pharmaceuticals-stock-down
Actinium-pharmaceuticals
Actinium-pharmaceuticals-inc
Analyst-recommendations-for-actinium-pharmaceuticals
News-ratings-for-actinium-pharmaceuticals-daily
Creative-financial-designs-inc
Brandywine-global-investment-management
Maxim-group
Cantor-fitzgerald
Free-report

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Given "Overweight" Rating at Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Actinium Pharmaceuticals (NYSEAMERICAN:ATNM – Free Report) in a research report report published on Tuesday morning, Benzinga reports. The firm currently has a $21.00 target price on the biotechnology company’s stock. Cantor Fitzgerald also issued estimates for Actinium Pharmaceuticals’ FY2024 earnings at ($1.35) EPS. Several other analysts […]

Actinium-pharmaceuticals
Actinium-pharmaceuticals-price-performance
Actinium-pharmaceuticals-inc
Analyst-recommendations-for-actinium-pharmaceuticals
Maxim-group
Cantor-fitzgerald
Creative-financial-designs-inc
News-ratings-for-actinium-pharmaceuticals-daily
Brandywine-global-investment-management
Sanders-morris-harris
Free-report

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Upgraded to "Hold" at StockNews.com

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Upgraded to "Hold" at StockNews.com
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Maxim-group
Actinium-pharmaceuticals-price-performance
News-ratings-for-actinium-pharmaceuticals-daily
Cantor-fitzgerald
Sanders-morris-harris
Brandywine-global-investment-management
Actinium-pharmaceuticals
Actinium-pharmaceuticals-inc
Analyst-recommendations-for-actinium-pharmaceuticals
Creative-financial-designs-inc
Free-report

Cantor Fitzgerald Comments on Actinium Pharmaceuticals, Inc.'s FY2024 Earnings (NYSEAMERICAN:ATNM)

Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM – Free Report) – Stock analysts at Cantor Fitzgerald boosted their FY2024 earnings estimates for shares of Actinium Pharmaceuticals in a report released on Tuesday, April 30th. Cantor Fitzgerald analyst K. Kluska now forecasts that the biotechnology company will post earnings of ($1.35) per share for the year, up from their […]

Actinium-pharmaceuticals
Maxim-group
Institutional-investors-weigh-in-on-actinium-pharmaceuticals
News-ratings-for-actinium-pharmaceuticals-daily
Actinium-pharmaceuticals-stock
Brandywine-global-investment-management
Creative-financial-designs-inc
Sanders-morris-harris
Actinium-pharmaceuticals-company-profile
Cantor-fitzgerald
Actinium-pharmaceuticals-inc

Actinium Pharmaceuticals' (ATNM) "Buy" Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Actinium Pharmaceuticals (NYSEAMERICAN:ATNM – Free Report) in a report released on Monday, Benzinga reports. The brokerage currently has a $50.00 price target on the biotechnology company’s stock. HC Wainwright also issued estimates for Actinium Pharmaceuticals’ Q2 2024 earnings at ($0.38) EPS, Q3 2024 earnings at ($0.45) […]

News-ratings-for-actinium-pharmaceuticals-daily
Brandywine-global-investment-management
Creative-financial-designs-inc
Cantor-fitzgerald
Actinium-pharmaceuticals-inc
Actinium-pharmaceuticals
Analyst-recommendations-for-actinium-pharmaceuticals
Actinium-pharmaceuticals-stock-performance
Sanders-morris-harris
Hedge-funds-weigh-in-on-actinium-pharmaceuticals
Maxim-group

vimarsana © 2020. All Rights Reserved.